StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics cash

Cash and short-term investments held at the end of each period.

Protagonist Therapeutics's cash was $782.58M at Jun 30, 2026. For fiscal 2025 it was $567.36M, up 35.4% from the year before. Over ten years it grew 63.9% a year on average. The highest annual figure on record is $567.36M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$567.36M+35.4%
FY2024Dec 31, 2024$419.14M+22.7%
FY2023Dec 31, 2023$341.62M+43.8%
FY2022Dec 31, 2022$237.58M-27.4%
FY2021Dec 31, 2021$327.13M+6.8%
FY2020Dec 31, 2020$306.27M+129.5%
FY2019Dec 31, 2019$133.48M+3.2%
FY2018Dec 31, 2018$129.31M+21.4%
FY2017Dec 31, 2017$106.49M+404.8%
FY2016Dec 31, 2016$21.09M+418.9%
FY2015Dec 31, 2015$4.07M-56.4%
FY2014Dec 31, 2014$9.33M+10.3%
FY2013Dec 31, 2013$8.46M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$782.58M+37.2%
Q1 FY2026Mar 31, 2026$547.79M-4.6%
Q4 FY2025Dec 31, 2025$567.36M+35.4%
Q3 FY2025Sep 30, 2025$576.12M+22.9%
Q2 FY2025Jun 30, 2025$570.47M+1.1%
Q1 FY2025Mar 31, 2025$574.36M+78.0%
Q4 FY2024Dec 31, 2024$419.14M+22.7%
Q3 FY2024Sep 30, 2024$468.72M+46.1%
Q2 FY2024Jun 30, 2024$564.00M+80.0%
Q1 FY2024Mar 31, 2024$322.64M+39.8%
Q4 FY2023Dec 31, 2023$341.62M+43.8%
Q3 FY2023Sep 30, 2023$320.75M+19.9%
Q2 FY2023Jun 30, 2023$313.40M+7.4%
Q1 FY2023Mar 31, 2023$230.76M-24.4%
Q4 FY2022Dec 31, 2022$237.58M-27.4%
Q3 FY2022Sep 30, 2022$267.44M-14.9%
Q2 FY2022Jun 30, 2022$291.89M-17.6%
Q1 FY2022Mar 31, 2022$305.29M+11.6%
Q4 FY2021Dec 31, 2021$327.13M+6.8%
Q3 FY2021Sep 30, 2021$314.30M+62.0%
Q2 FY2021Jun 30, 2021$354.28M+69.8%
Q1 FY2021Mar 31, 2021$273.48M+132.7%
Q4 FY2020Dec 31, 2020$306.27M+129.5%
Q3 FY2020Sep 30, 2020$193.97M+40.9%
Q2 FY2020Jun 30, 2020$208.67M+65.5%
Q1 FY2020Mar 31, 2020$117.51M+67.7%
Q4 FY2019Dec 31, 2019$133.48M+3.2%
Q3 FY2019Sep 30, 2019$137.69M+57.5%
Q2 FY2019Jun 30, 2019$126.10M+97.5%
Q1 FY2019Mar 31, 2019$70.08M+0.7%
Q4 FY2018Dec 31, 2018$129.31M+21.4%
Q3 FY2018Sep 30, 2018$87.43M+73.5%
Q2 FY2018Jun 30, 2018$63.86M+516.2%
Q1 FY2018Mar 31, 2018$69.58M+631.1%
Q4 FY2017Dec 31, 2017$106.49M+404.8%
Q3 FY2017Sep 30, 2017$50.40M-47.5%
Q2 FY2017Jun 30, 2017$10.37M–
Q1 FY2017Mar 31, 2017$9.52M–
Q4 FY2016Dec 31, 2016$21.09M–
Q3 FY2016Sep 30, 2016$96.02M–

More Protagonist Therapeutics figures

See a number that looks wrong?